Intravenous remifentanil patient-controlled analgesia can be used during labour as an alternative to epidural analgesia. Adverse effects of opioids, including hypoxia and bradycardia, may lead to maternal morbidity and mortality. We devised an interactive feedback system based on a clinical proportional algorithm, to continuously monitor for adverse effects to enhance safety and better titrate analgesia. This vital signs-controlled, patient-assisted intravenous analgesia with remifentanil used a prototype delivery system linked to a pulse oximeter that evaluated maternal oxygen saturation and heart rate continuously. With this system, we detected oxygen saturation < 95% for more than 60 s in 15 of 29 subjects (52%); and heart rate < 60 min À1 for more than 60 s in 7 of 29 subjects (24%) during use.
Introduction
Labour has been rated as one of the most severe pain experiences [1] . A neuraxial block is widely accepted as the 'gold standard' for analgesia, however, this may be medically contra-indicated, unavailable, or very difficult to perform. Alternatives such as intramuscular pethidine, nitrous oxide and oxygen mixture and other non-pharmacological methods have undesirable sideeffects and are generally ineffective.
The unique pharmacokinetic properties of remifentanil confer specific advantages for pain relief during labour. It has a fast onset and rapid hydrolysis by non-specific plasma and tissue esterases produces an ultra-short context-sensitive half-life of approximately 3-5 min, independent of the duration of infusion [2] . Although remifentanil crosses the placenta, it is quickly redistributed and eliminated in the fetus by placental and fetal esterases [3] . Patient-controlled analgesia (PCA) with remifentanil has been shown to confer modest analgesia in labouring parturients [4] and may be superior to pethidine [5, 6] .
However, as with other opioids, the use of remifentanil in labour is somewhat limited by maternal side-effects, including bradycardia, sedation and hypoventilation leading to hypoxia. The incidence of maternal oxygen desaturation (S p O 2 < 95%) has been reported as up to 74% with the use of remifentanil [7] . In general, these episodes tend to be short-lived and respond rapidly to stimulation and/or oxygen supplementation. Complete respiratory arrest, although rare, has been reported [8] [9] [10] [11] [12] .
Consequently, there is strong advocacy for continuous and careful physiological monitoring when remifentanil is used in labour [13] and maternal respiratory rate and oxygen saturation should be continuously monitored. To improve patient safety, we proposed that it could be beneficial to have an automated interactive system to modulate drug delivery based on the input of monitoring devices. We hypothesised that an interactive computer programme that studies the parturient's pattern of analgesic use and titrates the demand doses accordingly could improve safety. Hence, we developed a novel vital signs-controlled, patient-assisted intravenous analgesia (VPIA) system for administration of remifentanil during labour. In this system, the 'step-up-step-down' regimen is designed to enhance safety by initially administering small boluses. The dose is stepped up gradually when the patient makes active demands on the system by depressing the PCA button; and it is also programmed to step-down when the patient does not make demands on the PCA button over a defined period of time. In addition, this custom-made pump is coupled with a pulse oximeter which detects the parturient's oxygen saturation and heart rate ('Vital Signs') and feeds this into a dosing algorithm. By 'anticipating' the parturient's analgesic need while keeping these 'Vital Signs' within safety limits, our VPIA system aims to improve both the safety and efficacy of labour analgesia using remifentanil.
Our primary aim was to investigate the incidence of maternal oxygen desaturation (which we defined as a maternal oxygen saturation of < 95% for more than 60 s) when using VPIA remifentanil for labour pain.
Our secondary aims were to investigate the incidence of side-effects such as bradycardia, hypotension, apnoea/hypopnoea, sedation and nausea/vomiting as well as obstetric and anaesthetic outcomes such as pain scores, rate of conversion to epidural, total consumption of remifentanil and satisfaction score. Neonatal outcomes such as cord pH (arterial and venous) and Apgar scores (at 1 and 5 min) were also evaluated.
Methods
This case series was approved by the SingHealth Centralised Institutional Review Board. Written informed consent was obtained from every participant. Parturients in labour who required labour analgesia but either had contra-indications to or did not want to receive epidural analgesia were recruited. An information sheet describing the use of VPIA remifentanil for labour analgesia, including potential side-effects and complications, was provided to the subjects. Study personnel then took written informed consent while providing an option to withdraw from the study at any time. The parturients were followed-up from their admission to the delivery suite until assessment of maternal satisfaction was performed after delivery.
The following parturients were included: those who chose to use a parenteral opioid for pain relief, refused labour epidural analgesia or had a contra-indication to epidural analgesia (e.g. thrombocytopaenia, previous thoraco-lumbar spinal instrumentation). All had a gestational age of at least 36 weeks. Exclusion criteria were: parturients unable to understand instructions regarding the use of VPIA remifentanil or unable to self-administer VPIA boluses; difficulty in communication due to language differences; known hypersensitivity to remifentanil or any component of its formulation or to other fentanyl analogues; severe respiratory disease; history of drug dependence or recreational drug abuse; or known abnormality in fetal heart rate.
A novel clinical algorithm using smart-pump technology that converted an ordinary continuous infusion pump into a computer-integrated VPIA device was designed. This was analogous to the computerintegrated, patient-controlled epidural analgesia (CI-PCEA) that has been in use in our hospital since 2006 [14] . The VPIA hardware utilised a computer with a programmed algorithm that incorporated the information obtained from both the parturient's pattern of analgesic use as well as continuous maternal pulse oximetry and heart rate values as described in our earlier report [15] . When predefined critical values of S p O 2 or heart rate were reached, the pump would pause temporarily within the assigned lock-out period while the subsequent dose would be stepped down upon restarting the regimen. When the 'Vital Signs' were within the normal range, the bolus dose and/or basal infusion rate were titrated up or down based on the parturient's need. The detailed VPIA algorithm is shown in Fig. 1 .
Upon admission to the delivery suite, all study subjects had intravenous access established and external cardiotocography (Corometrics 250cx, GE Healthcare, UK) attached, which records baseline maternal blood pressure (BP), maternal heart rate, fetal heart rate and uterine activity. All patients received intravenous lactated Ringer's solution at a rate of 80 ml.h
À1
and supplemental oxygen at 4 l.min À1 via a face mask.
They were instructed on the use of the VPIA device before starting the study, and educated to press the demand button either at the beginning of a contraction or whenever a contraction was anticipated. All subjects were given a VPIA device containing 40 lg.ml À1 of remifentanil with an integrated pulse oximeter to continuously monitor the oxygen saturation and heart rate. Remifentanil was administered via the intravenous line with an anti-reflux and antisiphon valve.
The following baseline characteristics were collected upon enrolment: age; weight; height; parity; cervical dilatation; use of dinoprostone pessary for induction of labour; artificial rupture of membranes; and the use of oxytocin for augmentation of labour. Following initiation of VPIA remifentanil, the attending midwife who had been educated on the usage and side effects of remifentanil therapy, would monitor the patient at regular intervals, documenting maternal pain scores (0-10 numeric rating scale), blood pressure, heart rate, respiratory rate, arterial oxygen saturation and sedation score (0 for 'awake, alert', 1 for 'occasionally drowsy, easy to rouse, responds to calling', 2 for 'occasionally drowsy, difficult to rouse, responds to shaking only'; 3 for 'unresponsive and unarousable, defined as no response to voice or physical stimulation'; D for 'distressed, defined as awake and in great pain'). These were recorded by the attending midwife on a standardised data collection form. Maternal side-effects (e.g. nausea and vomiting) and obstetric data such as mode of delivery and duration of the second stage were also recorded. Upon delivery of the baby or conversion to epidural analgesia, the remifentanil pump was disconnected from the patient but monitoring still continued for at least another 30 min. Figure 1 The VPIA algorithm.
birth weight, Apgar scores at 1 and 5 min post-delivery and umbilical cord blood pH were documented. An independent observer visited the parturient the following day to assess overall maternal satisfaction (numerical score between 0% and 100%) with the labour analgesia provided.
Complications arising from remifentanil analgesic therapy were reported to the resident anaesthetist on duty immediately. In the event of inadequate labour analgesia using remifentanil, inhaled nitrous oxide and oxygen mixture was offered for additional pain relief. Alternatively, study subjects could opt for epidural analgesia at any time. In this case, data collected up to that point (e.g. pain scores, total and hourly usage of remifentanil and cervical dilatation at the point of cross-over) was used for analysis.
The primary outcome of the study was arterial oxygen desaturation in parturients; secondary outcomes were bradycardia; hypotension; apnoea/hypopnoea; sedation; nausea/vomiting; maternal pain scores; rate of conversion to epidural; total consumption of remifentanil; maternal satisfaction score; arterial cord pH; venous cord pH; and Apgar scores at 1 and 5 min. Association between infusion status and other covariates were tested using Fisher's exact test, student's t-test or Mann-Whitney U-test, as appropriate. A repeated measure analysis of variance (ANOVA) model was used to assess infusion status, time and interaction for VAS score. In order to determine a 50% incidence of maternal oxygen desaturation with a 95%CI and AE 0.175 margin of error, we needed to recruit 28 parturients based on a confidence interval approach. A p value < 0.05 was considered to be statistically significant and all the tests were two-sided. SAS version 9.3 software (SAS Institute, Cary, NC, USA) was used for analysis.
Results
We recruited 29 parturients over an 18-month period (November 2013-April 2015). Baseline characteristics are shown in Table 1 . Twenty-seven (93%) had at least one episode of oxygen saturation < 95% and in 15 (52%) it persisted for more than 60 s (Table 2) The lowest saturation recorded was 74.8%.
The median amount of remifentanil received during labour was 1.95 mg (0.07 mcg.kg
À1
.min À1 ), with a median duration of remifentanil use of 348 min (Table 2) . Nine (30%) parturients required additional analgesia. Eight of these received a mixture of nitrous oxide and oxygen and one converted to epidural analgesia.
The most common mode of delivery was normal vaginal delivery (18 of 29 (62%)), followed by eight cases undergoing caesarean section (28%) and three (10%) instrument-assisted vaginal deliveries (Table 3) .
A post-hoc analysis of the data found that 13 of the 29 patients required bolus doses only and did not tap into the infusion part of the regimen. However, 16 patients advanced in the algorithm to access an infusion as part of the remifentanil regimen, with five reaching the maximum infusion dose of 0.1 lg.kg (Table 4 ). Figure 2 shows VAS scores over time. The effects of time and interaction between time and infusion status were both significant for VAS score. It was also observed that there was no significantly different VAS score at any particular point of time.
Discussion
The use of PCA remifentanil for labour analgesia has been investigated in multiple randomised, controlled trials. However, the optimal dosing regimen has not yet been elucidated. Labour pain is dynamic; it constantly varies and often increases in frequency and intensity with time. In PCA, the bolus dose, timing and rate of bolus administration, lock-out intervals and use of a basal infusion can all be important factors in determining analgesic efficacy and safety. As an example, Volmanen and colleagues [16] reported wide inter-individual variation in the effective drug bolus (0.2-0.8 lg.kg
À1
) and drug consumption (0.027-0.207 lg.kg À1 .min
) amongst 20 parturients using PCA remifentanil. This suggests that a fixed-dose regimen may lead to under-dosing, causing analgesic failure or maternal dissatisfaction, or over-dosing, with its attendant side-effects. How best to utilise a basal infusion is currently unclear. In the literature, basal infusions, when used, have ranged from 0.025 to 0.15 lg.kg À1 .min
. Blair et al. [17] found that including a basal infusion did not result in significantly lower pain scores but only led to increased respiratory depression and sedation. In contrast, another study [18] attributed their remarkably low epidural conversion rate of 5% to their regimen of variable basal infusion (0.025-0.100 lg.kg
.min
) with an on-demand bolus dose of 0.25 lg.kg
. Balcioglu et al. [19] reported that parturients using remifentanil PCA with a basal infusion of 0.15 lg.kg À1 .min À1 had lower pain scores compared with those on a basal infusion of 0.1 lg.kg
.min À1 , without differences in maternal or fetal side-effects. Since the PCA settings have been widely variable across studies, a 'one size fits all' regimen that is safe and efficacious remains elusive. We used a novel clinical algorithm that converted an ordinary continuous infusion pump into a computer-integrated VPIA device. A key feature of our VPIA system is a safety lock-out. The pulse oximeter is the 'master' to the device, such that below a threshold reading, this would disable the pump, hence stopping further administration of remifentanil. The regimen only continues when the patient's oxygen saturation and heart rate return above the threshold. Even then, the pump is only allowed to resume at a lower bolus/infusion rate after the lock-out period. We believe this in-built safety mechanism is important in allowing the parturient sufficient time to recover from the potentially disastrous side-effects of respiratory depression.
Specifically, our system worked on the basis of good interaction between the delivery system and the parturient. When the parturient required pain relief, she pressed the PCA button and a pre-defined bolus dose was administered. If she continued to press the PCA button above a threshold number in a 15-min block, thus signalling inadequate pain relief, the bolus dose/infusion rate would be increased. Therefore, we have enabled the system to step-up the bolus doses as demand increases. Conversely, if the patient did not make demands above this threshold number on the PCA button, (signalling a possible relative overdose) the algorithm would 'step-down' and reduce the size of the bolus/infusion. During the entire time, the subject's oxygen saturation and heart rate would be monitored with the aim of stopping remifentanil administration if early signs of oxygen desaturation or bradycardia occurred. We chose the threshold values of 95% for maternal oxygen saturation and 60 beats.min À1 for maternal heart rate as an early sign of potential remifentanil overdose, thus allowing time for the effect of the drug to wear off and parturient to recover from the side-effects before any further remifentanil administration was allowed. We started all patients with a modest bolus dose of 20 lg without any infusion. As the pain level got higher, the algorithm was able to cater for this by increasing the bolus dose (from 20 lg to 50 lg in incremental doses of 10 lg). When patients required even more analgesia, the algorithm would be able to initiate an infusion. This infusion would start at 0.025 lg.kg
.min À1 and could be stepped up to 0.1 lg.kg
, depending on the requirements and pain level of the patient.
Researchers are developing smart pumps that can provide variable dosing [20] and algorithms are being written to 'predict' uterine contractions [21] . Predicting and matching the bolus/infusion dosage to the parturient is important, however, side-effects of maternal sedation and respiratory depression can still occur. The use of remifentanil for labour pain relief is known to cause maternal oxygen desaturation (SpO 2 < 95%), with an incidence ranging from 39% to 74% in previous studies [4, 7, 22] . In this study, we found that 27 parturients (93%) had at least one episode of oxygen saturation decreasing below 95% and in 15 (52%) it persisted for more than 60 s. Of note, only three (10%) parturients had oxygen saturation readings below 90% for more than 60 s, with the maximum duration being 190 s before recovery. Thus, these episodes are generally short-lived and quickly reversible with supplemental oxygen [4] . However, there are case reports of respiratory arrest associated with remifentanil use in labour [8, 9] and apnoea has been reported in a parturient on remifentanil infusion with associated fetal bradycardia that required emergency caesarean section [10] . There have been two separate cases of cardiac arrest presumably arising from remifentanilinduced respiratory arrest [11, 12] . Both patients made a full recovery following resuscitation, albeit with a perimortem caesarean section. None of the subjects in our study had significant bradypnoea (respiratory rate < 8 per min) or apnoea, as in most studies [17, 23] , suggesting that desaturation could have been contributed to by shallow breathing apart from a low respiratory rate. Also, the method of bradypnoea detection might not have been sufficiently sensitive as this was only measured manually at set time intervals, and not objectively recorded continuously by a respiratory rate monitor in our study. We also had no study subjects developing hypotension (systolic blood pressure < 90 mmHg) [18] . Remifentanil does not cause much sedation [4, 24] . All our patients were lightly sedated at most, and remained responsive throughout the study.
We found that 12 of 29 subjects (41%) had at least one episode where heart rate < 60 beats.min À1 , with only seven subjects (24%) experiencing this drop in heart rate for longer than a 60 s. This finding was in contrast to most studies on PCA remifentanil which did not report significant bradycardia (heart rate < 60 beats.min
). This could perhaps be explained by the differences in the way the heart rate data are collected. Our data were obtained by a computerised system that captures the heart rate of the subject every second. In a manual reporting system, many of these episodes of bradycardia may not be captured as it is dependent on the accuracy of the observer. Indeed, this disparity was highlighted in our case series as the incidence of bradycardia recorded on our manual reporting data collection form was zero.
In addition, relatively few parturients (17%) were reported to have nausea or vomiting in our study compared with the literature [7, 17, 18, 22] . All neonates had good outcomes as shown by cord blood pH and Apgar scores. By disallowing the continuation of the remifentanil PCA during a period of desaturation/ bradycardia, we believe that this device has the potential to increase the safety of using remifentanil in labour.
More than half of the subjects (55%) required the use of an infusion as part of their remifentanil regimen. However, the complications of desaturation and bradycardia did not appear to be different between these two groups despite an infusion being used. This could be attributed to the vital signs safety check which we had incorporated into the system, as well as the slow step-by-step build-up in the regimen. A larger study that is adequately powered would be required to confirm this. Also, in plotting the average pain score of the parturients over time (Fig. 2) , we found that all patients showed an improvement in pain scores in the initial hour of starting remifentanil PCA. Interestingly, for the group which required an infusion, the pain scores climbed back up towards the baseline level over the next few hours that had triggered the infusion. This was in contrast to the pain score remaining below baseline level for the group which did not require an infusion. However, after 4 h, the pain scores for both groups were indistinguishable. There was also a lack of correlation between satisfaction score and pain scores. In the study, median pain scores ranged between 4/10 and 8/10 and did vary considerably over the course of labour. Satisfaction score on the other hand, was an overall score recorded several hours after delivery of the baby. Apart from pain, satisfaction may be affected by other factors such as speed for which the pain relief was achieved as well as how supportive and responsive the hospital staff were towards her pain. We found that the venous cord blood pH was slightly lower in the group receiving an infusion but, as this was a posthoc analysis, limited conclusions can be drawn and further research should be performed. The median amount (1.95 mg) of remifentanil used was comparable to that of other studies [7, 17] , although we had a relatively high rate of nitrous oxide and oxygen coadministration (30%) to supplement VPIA remifentanil.
Although our VPIA system studies the patient's pattern of analgesic use in an attempt to deliver the optimal amount of remifentanil at any moment, the fixed 'step-up and step-down' algorithm might still not be responsive enough to the dynamic and ever-changing pattern of labour pain. Furthermore, it is known that the central nervous system effect of remifentanil peaks about 1-3 min after administration [4] . Patients can also be educated on anticipating the next contraction to improve the timing of the bolus-to-peak contraction. Perhaps a faster rate of injection for administering the bolus dose would help to reduce this time lag. Off-peak boluses might also be more effective [20] and incorporating cardiotocography monitoring into the VPIA algorithm may better time drug delivery [21] . The VPIA system may also be improved by incorporating further monitoring devices to improve its safety.
In conclusion, from this case series, we have shown that the prototype VPIA pump was able to increase the safety of using remifentanil analgesia. Although patient desaturation and bradycardia did occur, the immediate pausing of the pump was able to avert further desaturation and bradycardia.
